As the global Alzheimer's community enters a new era of drug treatments, we at MTC are excited to announce our collaboration with AIRAmed. This partnership will provide enhanced tools for the diagnosis and treatment of Alzheimer's patients. AIRAmed's cutting-edge technology allows patients to monitor their brain health through serial MRIs, which are conducted regularly during anti-amyloid therapy.
BONITA SPRINGS, Fla. , Sept. 27, 2024 /PRNewswire/ -- AIRAmed, a software company dedicated to the earlier detection of neurodegenerative diseases, more precise diagnoses, personalized treatments, and improving the quality of life for affected patients, is pleased to announce a research collaboration with Memory Treatment Centers.
In partnership with Dr. Donald McCarren (DO, FAAN, FAANEM), Dr. Samuel Giles (MD), Dr.
Robert Mannel (MD) and Dr. Jamie Plante (MD), the study will focus on quantitative brain volume measurements in cognitively impaired individuals receiving anti-amyloid treatment. Dr Tobias Lindig , Managing Director, AIRAmed said, "AIRAmed's vision and mission is to continuously improve patient care with cutting edge technology – especially in the field of neurodegenerative diseases.
We dedicate ourselves to early detection of disease. We developed our FDA-cleared AI-software AIRAscore - allowing to track changes in regional brain volume not visible to the eye. We are convinced that the partnership with MTC in this new era of treatments for Alzheimer ́s disease offers.
